While these perspectives may appear somewhat speculative at present, it is worth underlining that β3-AR agonists are already widely employed in humans - for indications unrelated to retinopathy - with excellent safety profiles and minimal adverse effects. The gene discussed is ADRB3; the disease is retinal disorder.